Showing 1811-1820 of 5771 results for "".
- Novartis Announces FDA and EMA Filing Acceptances of Beovu for Patients with Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-and-ema-filing-acceptances-of-beovu-for-patients-with-diabetic-macular-edema/2480351/Novartis announced that the FDA has accepted the company’s supplemental biologics license application (BLA) and that the European Medicines Agency (EMA) has validated the type-II variation application for Beovu (brolucizumab) 6 mg for the treatment of diabetic macular edema (DME).
- Oxurion Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-announces-first-patient-dosed-in-its-phase-2-study-evaluating-thr-687-for-the-treatment-of-dme/2480349/Oxurion announced that the first patient h
- Clearside Biomedical Delivers Podium and Poster Presentations at ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-delivers-podium-and-poster-presentations-at-asrs-annual-meeting/2480347/Clearside Biomedical announced that multiple presentations were given at the American Society of Retina Specialists (ASRS) Annual Meeting and at the OIS Retina Summit at ASRS, which took place October 7-12, 2021 in San Antonio, Texas. “The data pres
- Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Diabetic Retinal Disease to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meetinghttps://modernod.com/news/ocuphires-clinical-phase-2b-oral-drug-candidate-apx3330-for-diabetic-retinal-disease-to-be-featured-at-the-ois-retina-at-asrs-and-asrs-2021-annual-meeting/2480315/Ocuphire Pharma announced that its clinical-stage, novel oral Ref-1 inhibitor, APX3330, for the treatment of diabetic retinal disease will be featured at the Ophthalmology Innovation Summit (OIS) Retina@ASRS Innovation Company Showcase on October 7 in San Antonio, TX. The APX333
- Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studieshttps://modernod.com/news/apellis-announces-detailed-results-from-phase-3-derby-and-oaks-studies-presented-at-retina-society-annual-meeting/2480313/Apellis Pharmaceuticals announced that detailed data from the phase 3 DERBY and OAKS studies were presented for the first time as part of two oral presentations at the Retina Society Annual Scientific Meeting in Chicago.The studies evaluated the efficacy and safety of pegcetacoplan, an investigat
- AAO Updates Registration and Vaccination Requirement for Annual Meetinghttps://modernod.com/news/aao-updates-registration-and-vaccination-requirement-for-annual-meeting/2480306/The American Academy of Ophthalmology (AAO) announced that all in-person attendees of the AAO annual meeting in New Orleans will have to show proof of vaccination to enter the convention center using the Clear Health Pass app. A
- Aerie Pharmaceuticals Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEOhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-interim-executive-chair-and-departure-of-chairman-and-ceo/2480293/Aerie Pharmaceuticals announced that it is executing its succession plan and that effective September 17, 2021, Vicente Anido, PhD, no longer serves as the company’s Chairman and Chief Executive Officer or as a director of the company. Consistent with the succession plan in p
- Glaukos Announces Licensing Agreement with Attillaps Holdingshttps://modernod.com/news/glaukos-announces-licensing-agreement-with-attillaps-holdings-inc/2480289/Glaukos announced that it has entered into a licensing agreement with Attillaps Holdings under which Glaukos will gain a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compound
- Luneau Technology and Optovue Announce Mergerhttps://modernod.com/news/luneau-technology-and-optovue-announce-merger/2480284/France-based Luneau Technology Group, a provider of wavefront-based diagnostic and finishing solutions, announced it is merging with Optovue. Terms of the deal were not disclosed. Founded by Jay Wei in 2003, Optovue develops high-speed OCT and OCT-A technology
- J&J Vision Announces New Collaboration Aimed at Eliminating Inequities in the Eye Care Industryhttps://modernod.com/news/johnson-johnson-vision-announces-new-collaboration-aimed-at-eliminating-inequities-in-the-eye-care-industry/2480280/Johnson & Johnson Vision announced a collaboration with